When Marissa Solan joined Haleon in July after it split from GSK, she told PRWeek the U.S. communications team had two objectives: Establish Haleon’s new identity as a consumer healthcare company and “develop best-in-class earned programs for its portfolio of brands.”
Looking at the independent company’s earnings report from September and seeing strong performances of products including Theraflu, Advil and Centrum, it’s evident Solan’s team succeeded at the latter. Another subsidiary, headache relief company Excedrin, recently stepped into the world of NFTs with its Equal Bytes program, an initiative that guarantees women creators sales of their first NFTs with $800 bids.
Solan worked on similarly purposeful initiatives in her previous role as SVP at Edelman. She handled efforts that assured people, especially women, of their natural beauty, including Dove’s Real Beauty Sketches, Choose Beautiful, #SpeakBeautiful, the U.S. launch of Baby Dove and the 60th anniversary of the Dove Beauty Bar.
Haleon has dealt with ongoing liability issues surrounding Zantac, a heartburn drug containing low levels of a carcinogen, and a resulting sharp drop in shares due to investor concerns. Still, Solan and her team are poised to take advantage of a strong first half of 2022.